Skip to content

Study · Systematic review · n = 629 · 2019

8 results

The Influence of Liraglutide for Heart Failure: A Meta-Analysis of Randomized Controlled Trials.

Zhang Y, Chen Q, Huang G, Wang L

The heart surgery forum14 Oct 2019Cited by 4 (Europe PMC)

PMID31895026 (opens in a new tab)DOI10.1532/hsf.2513 (opens in a new tab)PepBankPUB-31895026
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with heart failure, liraglutide significantly reduced NT-proBNP compared with control.

    In plain wordsIn adults with heart failure, liraglutide lowered NT-proBNP, a heart strain marker, compared with control.

    Peptide
    Liraglutide
    Outcome
    DecreaseNT-proBNP
    Study

    n = 629

    Comparator
    Control group for heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Standardised mean difference
    −3.06 Std. MD
    NT-proBNP

    Source sentences

    Summary
    Overall, compared with the control group for heart failure, liraglutide treatment significantly can reduce NT-proBNP (Std. MD = -3.06; 95% CI = -5.78 to -0.34; P = .03), and improve 6MWT (Std.
    1 context sentence
    Summary · context
    We searched PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases through March 2018 for randomized controlled trials (RCTs) assessing the effect of liraglutide on cardiac function of heart failure.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with heart failure, liraglutide significantly improved 6MWT compared with control.

    In plain wordsIn adults with heart failure, liraglutide improved the 6-minute walk distance compared with control.

    Peptide
    Liraglutide
    Outcome
    Increase6-minute walk test
    Study

    n = 629

    Comparator
    Control group for heart failure
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Standardised mean difference
    1.1 Std. MD
    6MWT

    Source sentences

    Summary
    MD = -3.06; 95% CI = -5.78 to -0.34; P = .03), and improve 6MWT (Std. MD=1.10; 95% CI = 0.75 to 1.44; P < .00001), but has no remarkable influence on LVEF change (Std.
    1 context sentence
    Summary · context
    We searched PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases through March 2018 for randomized controlled trials (RCTs) assessing the effect of liraglutide on cardiac function of heart failure.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with heart failure, liraglutide had no significant effect on LVEF change.

    In plain wordsIn adults with heart failure, liraglutide did not change the heart's pumping fraction (LVEF).

    Peptide
    Liraglutide
    Outcome
    No significant changeLVEF change
    Study

    n = 629

    Comparator
    Control group for heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MD=1.10; 95% CI = 0.75 to 1.44; P < .00001), but has no remarkable influence on LVEF change (Std. MD=1.10; 95% CI = -1.97 to 3.98; P = 0.51), LVEDV change (Std.
    1 context sentence
    Summary · context
    We searched PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases through March 2018 for randomized controlled trials (RCTs) assessing the effect of liraglutide on cardiac function of heart failure.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with heart failure, liraglutide had no significant effect on LVEDV change.

    In plain wordsIn adults with heart failure, liraglutide did not change the heart's end-diastolic volume.

    Peptide
    Liraglutide
    Outcome
    No significant changeLVEDV change
    Study

    n = 629

    Comparator
    Control group for heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MD=1.10; 95% CI = -1.97 to 3.98; P = 0.51), LVEDV change (Std. MD = 6.26; 95% CI = -1.45 to 13.97; P = .11), LVESV change (Std.
    1 context sentence
    Summary · context
    We searched PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases through March 2018 for randomized controlled trials (RCTs) assessing the effect of liraglutide on cardiac function of heart failure.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with heart failure, liraglutide had no significant effect on LVESV change.

    In plain wordsIn adults with heart failure, liraglutide did not change the heart's end-systolic volume.

    Peptide
    Liraglutide
    Outcome
    No significant changeLVESV change
    Study

    n = 629

    Comparator
    Control group for heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MD = 6.26; 95% CI = -1.45 to 13.97; P = .11), LVESV change (Std. MD = -13.47; 95% CI = -31.04 to 4.10; P = .13), hospitalization for heart failure (RR = 1.18; 95% CI = 0.88 to 1.58; P = .27), major adverse cardiovascular events (RR = 1.55; 95% CI = -0.24 to 9.89; P = .64), and cardiac death (RR = 1.…
    1 context sentence
    Summary · context
    We searched PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases through March 2018 for randomized controlled trials (RCTs) assessing the effect of liraglutide on cardiac function of heart failure.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with heart failure, liraglutide had no significant effect on hospitalization for heart failure.

    In plain wordsIn adults with heart failure, liraglutide did not change the number of hospital stays for heart failure.

    Peptide
    Liraglutide
    Outcome
    No significant changeHospitalization for heart failure
    Study

    n = 629

    Comparator
    Control group for heart failure
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    1.18 RR
    hospitalization for heart failure

    Source sentences

    Summary
    hospitalization for heart failure (RR = 1.18; 95% CI = 0.88 to 1.58; P = .27)
    1 context sentence
    Summary · context
    We searched PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases through March 2018 for randomized controlled trials (RCTs) assessing the effect of liraglutide on cardiac function of heart failure.
  7. 07HumanSystematic reviewEfficacy outcome

    In adults with heart failure, liraglutide had no significant effect on major adverse cardiovascular events.

    In plain wordsIn adults with heart failure, liraglutide did not change the number of major heart events.

    Peptide
    Liraglutide
    Outcome
    No significant changeMajor adverse cardiovascular events
    Study

    n = 629

    Comparator
    Control group for heart failure
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    1.55 RR
    MACE

    Source sentences

    Summary
    major adverse cardiovascular events (RR = 1.55; 95% CI = -0.24 to 9.89; P = .64)
    1 context sentence
    Summary · context
    We searched PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases through March 2018 for randomized controlled trials (RCTs) assessing the effect of liraglutide on cardiac function of heart failure.
  8. 08HumanSystematic reviewEfficacy outcome

    In adults with heart failure, liraglutide had no significant effect on cardiac death.

    In plain wordsIn adults with heart failure, liraglutide did not change the number of heart-related deaths.

    Peptide
    Liraglutide
    Outcome
    No significant changeCardiac death
    Study

    n = 629

    Comparator
    Control group for heart failure
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    1.11 RR
    cardiac death

    Source sentences

    Summary
    cardiac death (RR = 1.11; 95% CI = 0.61 to 2.04; P = .72).
    1 context sentence
    Summary · context
    We searched PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases through March 2018 for randomized controlled trials (RCTs) assessing the effect of liraglutide on cardiac function of heart failure.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.